Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 5/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.58 |
| ▸ | CNR2 | P34972 | 4/20 | 0.55 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KRAS | P01116 | 1/20 | 0.47 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.44 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3318082 | 0.99 | BAZ2B (0.57) | BAZ2BHDAC1HDAC6CNR2PTGDR2 | |
| SCHEMBL1120480 | 0.91 | CNR2 (0.54) | BAZ2BHDAC1HDAC6CNR2KMT2A | |
| SCHEMBL3322108 | 0.91 | BAZ2B (0.60) | BAZ2BHDAC1HDAC6CNR2PTGDR2 | |
| SCHEMBL17029246 | 0.89 | HDAC6 (0.56) | HDAC1HDAC6PTGDR2KMT2AKRAS | |
| SCHEMBL17029244 | 0.88 | HDAC6 (0.55) | HDAC1HDAC6PTGDR2KMT2AKRAS | |
| SCHEMBL13534097 | 0.82 | HDAC1 (0.55) | BAZ2BHDAC1HDAC6PTGDR2PTGER2 | |
| SCHEMBL15132702 | 0.82 | BAZ2B (0.65) | BAZ2BHDAC1HDAC6PTGDR2PTGER2 | |
| SCHEMBL3319843 | 0.82 | BAZ2B (0.76) | BAZ2BHDAC1HDAC6PTGDR2PTGER2 | |
| SCHEMBL4138425 | 0.82 | HDAC1 (0.55) | BAZ2BHDAC1HDAC6PTGDR2KMT2A | |
| SCHEMBL3238010 | 0.81 | HSD17B10 (0.53) | HDAC1HDAC6CNR2PTGDR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115137-B2 | 2,3,4,5-tetrahydro-1H-pyrido[4,3-B]indole compounds and methods of use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115137-B2 | 2,3,4,5-tetrahydro-1H-pyrido[4,3-B]indole compounds and methods of use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115137-B2 | 2,3,4,5-tetrahydro-1H-pyrido[4,3-B]indole compounds and methods of use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| EP-2244708-B1 | NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES INC (US) | 2015-01-14 | — | — | EP | disclosed |
| EP-2244708-B1 | NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES INC (US) | 2015-01-14 | — | — | EP | disclosed |
| US-20130190348-A1 | NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO [4,3-B] INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190348-A1 | NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO [4,3-B] INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190348-A1 | NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO [4,3-B] INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190347-A1 | 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190347-A1 | 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190347-A1 | 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| EP-2244708-A1 | NEW 2,3,4,5-TEtRAHYDRO-1H-PYRIDO [4,3-B] INDOLE COMPOUNDS AND METHODS OF USE THEREOF | Medivation Technologies, Inc. (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20100022580-A1 | NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES, INC. | 2010-01-28 | — | — | US | disclosed |
| US-20100022580-A1 | NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES, INC. | 2010-01-28 | — | — | US | disclosed |
| US-20100022580-A1 | NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES, INC. | 2010-01-28 | — | — | US | disclosed |
| WO-2009094668-A1 | NEW 2,3,4,5-TERAHYDRO-1H-PYRIDO[ 4,3-B] INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009094668-A1 | NEW 2,3,4,5-TERAHYDRO-1H-PYRIDO[ 4,3-B] INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190347-A1 | 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF | HTR2C, HTR3B, HTR4 | BAZ2B 1845/4885HDAC1 4020/4885HDAC6 3290/4885 |
| US-20100022580-A1 | NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF | HTR2C, HTR3B, HTR4 | BAZ2B 1712/4885HDAC1 3809/4885HDAC6 2802/4885 |
| US-20130190348-A1 | NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO [4,3-B] INDOLE COMPOUNDS AND METHODS OF USE THEREOF | HTR2C, HTR3B, HTR4 | BAZ2B 1712/4885HDAC1 3809/4885HDAC6 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.